5J2.F GABATHER AB (PUBL) SK-44

Healthcare Pharmaceuticals Frankfurt Exchange
0.0002 EUR
Close of Nov 4, 2026
0.0002 0.0090
Market cap
EUR 122K
P/E
-
P/B
0.92x
ROE
-292.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 5J2.F undervalued?

Graham number

The Graham number of GABATHER AB (PUBL) SK-44 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GABATHER AB (PUBL) SK-44 fundamental analysis

No fundamental analysis for GABATHER AB (PUBL) SK-44 yet.

GABATHER AB (PUBL) SK-44 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GABATHER AB (PUBL) SK-44

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. It offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. The company focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer's disease, schizophrenia, and major depressive disorders. Gabather …

Full company profile